Stoke Therapeutics, Inc. - 8-K Filing
Stoke Therapeutics reported Q1 2026 revenue of $6.2 million, a net loss of $50.0 million ($0.79 per share), and cash reserves of $411.0 million as of March 31, 2026, which the company expects to fund operations through 2028. The firm also announced new four-year data from its Phase 1/2a open-label extension studies showing durable seizure reductions and cognitive improvements with zorevunersen for Dravet syndrome, while enrollment in the Phase 3 EMPEROR trial is expected to finish by June 2026 ahead of a mid-2027 readout. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $STOK